Undisclosed SMARCA2 Degrader / Dr. Reddy’s - LARVOL DELTA

Discovery of highly selective, potent and orally bio-available SMARCA2 degraders (AACR 2025) - "Here, we report the identification and development of highly selective SMARCA2 degrader with oral bioavailability that have demonstrated robust efficacy in SMARCA4 mutant CDX models...Further, the identified degrader demonstrated robust efficacy supported by SMARCA2 degradation in multiple SMARCA4-mutant CDX models, at well-tolerated doses. Repeat dose tolerability profile of the lead compound in non-rodent species is ongoing towards candidate nomination."

Oncology • SMARCA2 • SMARCA4